

AMENDMENTS TO THE CLAIMS

Please replace all previous versions and listings of the claims with the following claims, wherein text to be deleted is indicated by strikethrough and text to be added is indicated by underlining.

1. (currently amended) A method of reducing a T cell-mediated immune response in an individual diagnosed as having a condition characterized by an excessive or unwanted T cell-mediated immune response; ~~and, the method comprising:~~

administering to the individual a composition comprising an effective amount of an apoptosis-inducing anti-PSGL-1 antibody or antigen-binding fragment thereof wherein the antibody or antigen-binding fragment specifically binds to P-Selectin Glycoprotein Ligand-1 (PSGL-1) on the surface of a T cell, wherein the binding of the antibody or antigen-binding fragment thereof to PSGL-1 on the surface of the T cell induces ~~a signal transduction pathway that results in the death~~ apoptosis of the T cell, thereby reducing a T cell-mediated immune response in the individual.

2. (canceled)

3. (previously presented) The method of claim 1, wherein the antibody is a monoclonal antibody that specifically binds to PSGL-1.

4. (currently amended) The method of claim 3, further comprising administering an antibody that binds to the monoclonal antibody and induces ~~the~~ cross-linking of a plurality of PSGL-1 antigens on the surface of the T cell.

5. (canceled)

6. (currently amended) The method of claim 1, ~~comprising selecting an individual diagnosed as having~~ wherein the condition characterized by an excessive or unwanted T cell-mediated immune response is an autoimmune disease.

7. (withdrawn) The method of claim 1, comprising selecting an individual that has received or is expected to receive an allogeneic or xenogeneic transplant.

8. (withdrawn) The method of claim 1, comprising selecting an individual diagnosed as having an allergic disease.

9. (withdrawn) The method of claim 1, comprising selecting an individual diagnosed as having a T cell cancer.

10. (original) The method of claim 1, wherein the T cell is an activated T cell.

11. (previously presented) The method of claim 1, wherein the T cell is a CD4⁺ T cell.

12. (previously presented) The method of claim 1, wherein the T cell is a CD8⁺ T cell.

13. (currently amended) The method of claim 1, ~~wherein the method comprises~~ further comprising:

detecting ~~the~~ a number of T cells in a first biological sample taken from the individual before the administration of the composition; and

comparing the number of T cells detected in the first biological sample with ~~the~~ a number of T cells in a second biological sample taken from the individual after the administration of the composition.

14-16. (canceled)

17. (currently amended) A method of inducing the death of a T cell or a natural killer (NK) cell, the method comprising:

providing a T cell or NK cell expressing PSGL-1 on its cell surface; and

contacting the T cell or NK cell with an effective amount of an apoptosis-inducing anti-PSGL-1 antibody or antigen-binding fragment thereof wherein the antibody or antigen-binding fragment thereof specifically binds to PSGL-1 on the surface of the T cell or NK cell, wherein the binding of the antibody or antigen-binding fragment thereof to PSGL-1 on the surface of the T cell or NK cell induces ~~a signal transduction pathway that results in the death~~ apoptosis of the T cell or NK cell.

18. (canceled)

19. (previously presented) The method of claim 17, wherein the antibody is a monoclonal antibody that specifically binds to PSGL-1.

20. (currently amended) The method of claim 19, further comprising contacting the monoclonal antibody with an antibody that binds to the monoclonal antibody and induces the cross-linking of a plurality of PSGL-1 antigens on the surface of the T cell or NK cell.

21. (canceled)

22. (currently amended) The method of claim 17, wherein the T cell or NK cell is an activated T cell.

23. (currently amended) The method of claim 17, wherein the T cell or NK cell is a CD4⁺ T cell.

24. (currently amended) The method of claim 17, wherein the T cell or NK cell is a CD8⁺ T cell.

25. (currently amended) The method of claim 17, ~~wherein the method comprises~~ further comprising assessing ~~the~~ viability of the T cell or NK cell after the contacting with the antibody or antigen-binding fragment thereof.

26-37. (canceled)

38. (new) The method of claim 17, wherein the T cell or NK cell is an NK cell.